Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study

Abstract

Background: The incidence of well-differentiated gastric neuroendocrine tumors (G-NET) is increasing annually, and while they have a good prognosis and low mortality rate, their high recurrence rate makes treatment options controversial. This study aims to determine the relationship between individualized treatment plans and the recurrence of G-NET. Methods: We performed a multicenter, retrospective study of 94 patients with highly differentiated G-NET and treated at Peking Union Medical College Hospital, Yantai Yuhuangding Hospital and Beijing Zhong-Neng-Jian Hospital from November 2015 to September 2023. Risk factors for recurrence of G-NETs were investigated using one-way chi-squared test and multifactorial logistic regression analysis. Results: After a median follow-up of 49 months, the overall recurrence rate among the 94 G-NET patients was 14% (13/94). The recurrence rates of endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), somatostatin analog (SSA) therapy, and surgery were 43% (6/14), 10% (5/49), 5% (1/22), and 11% (1/9), respectively. Post-treatment recurrence rates were significantly different (P = 0.014) among four treatments (EMR, ESD, SSA, and surgery), and further subgroup comparisons revealed lower recurrence rates in the ESD and SSA groups than in the EMR group. From the second month onward, SSA therapy considerably reduced the gastrin levels from 1081 (571.5, 2472.8) pg/mL to 461.5 (255.3, 795.0) pg/mL (Z = –3.521, P = 0.000). Both chi-squared test and multifactorial logistic regression analysis suggested that among the clinicopathological parameters studied, only the pre-treatment gastrin level (P = 0.018 and 0.005) and the type of treatment (P = 0.014 and 0.017) were significantly associated with G-NET recurrence. Conclusions: Individualized treatment strategies may reduce the risk of relapse after G-NET treatment. Long-term SSA therapy may be a secure and efficacious treatment option for type 1 G-NET with more than six lesions, and it substantially decreases the incidence of post-treatment recurrence.

Neuroendocrine Neoplasia: From Pathophysiology to Novel Therapeutic Approaches

“…Notably, another recent multi-centric study on welldifferentiated gastric NENs (N = 94, median follow-up of 49 months) showed a recurrence rate of 14%; the most important parameters that served as indexes of recurrence comprised the pre-therapy level of gastrin and the choice of therapy. In this cohort, the lowest recurrence rates were found in subjects who were treated with somatostatin analogues (SSAs) (5%) and those who underwent an endoscopic submucosal dissection (10%) [22].…”